Medtronic completes acquisition of Invatec

6056

Medtronic announced on 21 April 2010 that it has completed the acquisition of Invatec. The acquisition includes two affiliated companies: Fogazzi, which provides proprietary polymer technology to Invatec; and Krauth Cardio-Vascular, which has successfully grown Invatec’s market position in Germany.

Invatec has been recognised for developing novel devices for the treatment of coronary and peripheral vascular disease in collaboration with physicians, researchers and scientists. Medtronic intends to build on Invatec’s legacy of innovation through collaboration to improve and expand treatment options for patients with cardiovascular disease.


“With this acquisition, Medtronic is enhancing its international presence by further developing our global business with additions to our European operations,” said Scott Ward, president of the CardioVascular business and senior vice president at Medtronic. “Medtronic’s acquisition of Invatec will accelerate the growth of our CardioVascular business, adding important new coronary and peripheral vascular products to our current offering.”


The newly added business will be led by general manager, Ross Allen, a 19-year veteran of Medtronic with leadership experience across four divisions, most recently as vice president of finance for the CardioVascular business. Invatec’s founders will stay with the new business in senior leadership positions: Andrea Venturelli as vice president of research and development and chief technology officer; and Stefan Widensohler as vice president of global sales.


Medtronic plans to maintain Invatec’s European operations in order to stay close to the existing core customer base in Europe, the source of many collaborative innovations that have advanced the treatment of cardiovascular disease. To ensure the continuity of these operations, Medtronic purchased Invatec facilities in Brescia, Italy and the lease on an existing facility in Frauenfeld, Switzerland has been extended.


Invatec pioneered the development and commercialisation of lesion-specific solutions for coronary and peripheral vascular disease.

  • For below-the-knee disease, Invatec was the first company to make and market a percutaneous transluminal angioplasty balloon, self-expanding stent, balloon-expandable stent and guidewire specifically designed for that indication.
  • For carotid artery disease, Invatec designed and commercialised a stent to provide ease of delivery and adequate coverage of the lesion. Products also include a proximal and distal embolic protection device, providing a complete solution for the treatment of atherosclerosis in the carotid artery.
  • In addition, Invatec led the introduction of a new treatment platform with its four drug-eluting balloons, covering the coronaries and lower-extremity vessels.

Of these therapies, only devices for the treatment of below-the-knee disease are currently approved for use in the United States.